Syndromic Diagnostics And Automation Will Shape Future Healthcare

Published
23 Aug 24
Updated
20 Aug 25
AnalystConsensusTarget's Fair Value
US$52.39
5.1% undervalued intrinsic discount
20 Aug
US$49.74
Loading
1Y
4.5%
7D
0.8%

Author's Valuation

US$52.4

5.1% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 6.23%

Shared on30 Apr 25
Fair value Decreased 0.66%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Increased 0.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.62%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 0.64%

AnalystConsensusTarget has decreased revenue growth from 6.3% to 5.4%.

Shared on02 Apr 25
Fair value Decreased 6.81%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Increased 8.71%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Increased 0.44%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.